Vaccine Development

Mar 22, 2016
By BioPharm International Editors
The Human Vaccines Project brings together academic research centers, industrial partners, nonprofit organizations, and governments to address the primary scientific barriers to developing new vaccines and immunotherapies.
Mar 18, 2016
By BioPharm International Editors
During a clinical trial of 48 participants, 100% of those that received the TV003 vaccine were protected from infection.
Feb 11, 2016
Vaccine R&D has grown exponentially in recent years, spurred by ethical and medical needs to combat lethal infectious outbreaks and increased funding from public and private agencies and organizations.
Dec 03, 2015
By BioPharm International Editors
Seqirus, CSL Limited’s influenza vaccine business, announced the opening of their corporate headquarters in the United Kingdom.
Nov 13, 2015
BioPharm International
Panelists at the meeting will focus on clinical trial design, immunogenicity, and enhancing implementation plans for administering already-licensed vaccines to this patient population.
Nov 05, 2015
By BioPharm International Editors
South Africa’s Biovac Institute, which develops and produces vaccines for the country, launched a public-private partnership with Pfizer to enable local manufacturing of Prevenar 13, a vaccine against pneumonia-causing bacteria.
Oct 23, 2015
By BioPharm International Editors
Univercells will integrate its single-use bioprocess with the Takeda vaccines production platform to allow local production.
Sep 16, 2015
By BioPharm International Editors
Novovax’s investigational vaccine targeting respiratory syncytial virus (RSV) demonstrated clinical effectiveness in animal models.
Aug 13, 2015
By BioPharm International Editors
CMC Biologics will manufacture monoclonal antibodies (mAbs) and provide process development services for the PATH Malaria Vaccine Initiative.
Jul 24, 2015
By BioPharm International Editors
GSK’s malaria candidate vaccine for the prevention of malaria in young children received a positive opinion from EMA.
native1_300x100
lorem ipsum